Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:56 PM
Ignite Modification Date:
2025-12-24 @ 5:56 PM
NCT ID:
NCT01598168
Eligibility Criteria:
Inclusion Criteria:
* Adult patients with 4T's Score greater than or equal to 4.
Exclusion Criteria:
* Require ongoing anticoagulant therapy for a mechanical heart valve.
* Severe renal insufficiency (CrCl\<30 ml/min)
* Hepatic disease (including Child-Pugh B and C) associated with coagulopathy and a clinically relevant bleeding risk
* Inability to take oral medications.
* Ongoing requirement for systemic treatment with azole-antimycotics (except fluconazole) or HIV-protease inhibitors or strong CYP3A4 inducers
* Clinically significant active bleeding or lesions at increased risk for bleeding within the last 6 months
* Platelet count less than 80 and an ongoing need for antiplatelet therapy may be excluded at the discretion of the investigator
* Pregnant or a woman of child-bearing potential not using an adequate birth control method
* Hypersensitivity to rivaroxaban or to any ingredient in the formulation.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01598168
Study Brief:
Protocol Section:
NCT01598168